Exosomes tied with PRP — but both sides got RF microneedling first

A 2025 investigator-blinded, split-face non-inferiority trial.

The design, precisely:

• Both halves of the face received three sessions of radiofrequency microneedling
• Immediately after, one half received PRP
• The other half had exosomes applied
• The assessors did not know which side was which

The result: wrinkling, dyschromia, erythema and texture all improved equally on both sides.

Since this was a non-inferiority trial, the result came out as designed. The authors asked not 'are exosomes better than PRP' but 'are exosomes not worse than PRP', and the answer was 'not worse'.

Now the limitation. This is the most important paragraph on the page.

Both halves of the face received radiofrequency microneedling. So the trial cannot distinguish between three possibilities:

1. Exosomes and PRP both work, and work similarly
2. Neither works, and the improvement was entirely the device's doing
3. Only one works, but the device's effect was large enough to bury the difference

All three produce the same result.

The PRP page on this site shows why that matters in practice. There, a trial put saline in the other cheek, and the blinded raters could not tell PRP from saline. If that result holds, then what exosomes tied with here was something that was indistinguishable from saline.

This is the fundamental problem with non-inferiority designs: 'not worse' only means something once you know whether the comparator works.

Also, the abstract does not report the number of participants or the follow-up period. We have left those fields blank rather than fill them in.

This is the histology from the same trial. Not a new study.

Collagen I and glycosaminoglycans (GAGs) increased. And there was no significant difference between the arms.

Biopsy is a valuable endpoint in this layer. Unlike photo scores or self-ratings, it looks at what actually changed inside the skin. There is little room for expectation or lighting to enter.

So the finding that collagen increased does mean something on its own. Something happened in the skin.

But the limitation from the item above applies here exactly as much. Both halves received radiofrequency microneedling, and that device works by delivering heat and physical injury to the dermis to provoke a repair response. The trial cannot exclude the possibility that the device is what raised the collagen.

It is more accurate to read it this way: the fact that both sides rose equally means the material laid on top did not separate the histology.

One more thing: more collagen and looking better are different claims. The PLLA and CaHA pages on this site deal with the same problem. How much a change in tissue shows up in the mirror is a separate question.

We did not find a human trial comparing exosomes against an inert control.

That is this page's conclusion.

What we found was exosomes versus PRP, and even there both sides also received the device treatment. There is no 'nothing applied' side.

Why that matters, again. Across the whole procedures layer of this site, only two trials so far have used an inert control: IPL and PRP. One of the two beat its control and one did not. The point is that you could not have known in advance.

So what we can currently say about exosomes is this:

• Indistinguishable from PRP when used alongside the device — established
• A change was observed in tissue — established, but not separated from the device
• Are exosomes themselves better than nothing — not established

Telling you plainly that the third line is empty is what this page is for.

We also note that the source material (human adipose-derived stem cells, plants, bacteria and others), particle counts and purification methods differ between products. The single word 'exosome' does not denote the same thing throughout. That is why the result of the one trial above cannot be carried over to another product.